Cofactor Genomics said it has become a member of the Foundation for NIH Biomarkers Consortium with the goal of advancing the adoption of multidimensional biomarkers in cancer and immune-related diseases.
Formally launched in 2006, the FNIH Biomarkers Consortium is a major public-private biomedical research partnership managed by the FNIH with broad participation from stakeholders across biomedical research, including government, industry, academia, patient advocacy, and other not-for-profit organizations.
In addition to the FNIH, founding members include NIH, FDA, the Pharmaceutical Research and Manufacturers of America, the Centers for Medicare & Medicaid Services, and BIO.
The FNIH Biomarkers Consortium brings together expertise and resources of various partners to rapidly identify, develop, and seek qualification of potential high-impact biomarkers particularly to enable improvements in drug development, clinical care, and regulatory decision-making.
Cofactor’s success in demonstrating the utility of Predictive Immune Modeling with their ImmunoPrism assay positions them to add value to a number of the initiatives of the FNIH Biomarkers Consortium, specifically in the area of inflammation, immunity, and cancer.
Cofactor’s technical teams will participate in the FNIH Biomarkers Consortium and offer expertise in ImmunoPrism reagents and services to achieve advanced profiling of immune response.
